Genomic diversity improves disease discovery for all

Alice Williamson,Segun Fatumo

DOI: https://doi.org/10.1126/science.adq7784

IF: 56.9

2024-07-19

Science

Abstract:Genomic data from different populations will improve understanding of complex diseases

multidisciplinary sciences

What problem does this paper attempt to address?

Genetic analyses of diverse populations improves discovery for complex traits

Genevieve L. Wojcik,Mariaelisa Graff,Katherine K. Nishimura,Ran Tao,Jeffrey Haessler,Christopher R. Gignoux,Heather M. Highland,Yesha M. Patel,Elena P. Sorokin,Christy L. Avery,Gillian M. Belbin,Stephanie A. Bien,Iona Cheng,Sinead Cullina,Chani J. Hodonsky,Yao Hu,Laura M. Huckins,Janina Jeff,Anne E. Justice,Jonathan M. Kocarnik,Unhee Lim,Bridget M. Lin,Yingchang Lu,Sarah C. Nelson,Sung-Shim L. Park,Hannah Poisner,Michael H. Preuss,Melissa A. Richard,Claudia Schurmann,Veronica W. Setiawan,Alexandra Sockell,Karan Vahi,Marie Verbanck,Abhishek Vishnu,Ryan W. Walker,Kristin L. Young,Niha Zubair,Victor Acuña-Alonso,Jose Luis Ambite,Kathleen C. Barnes,Eric Boerwinkle,Erwin P. Bottinger,Carlos D. Bustamante,Christian Caberto,Samuel Canizales-Quinteros,Matthew P. Conomos,Ewa Deelman,Ron Do,Kimberly Doheny,Lindsay Fernández-Rhodes,Myriam Fornage,Benyam Hailu,Gerardo Heiss,Brenna M. Henn,Lucia A. Hindorff,Rebecca D. Jackson,Cecelia A. Laurie,Cathy C. Laurie,Yuqing Li,Dan-Yu Lin,Andres Moreno-Estrada,Girish Nadkarni,Paul J. Norman,Loreall C. Pooler,Alexander P. Reiner,Jane Romm,Chiara Sabatti,Karla Sandoval,Xin Sheng,Eli A. Stahl,Daniel O. Stram,Timothy A. Thornton,Christina L. Wassel,Lynne R. Wilkens,Cheryl A. Winkler,Sachi Yoneyama,Steven Buyske,Christopher A. Haiman,Charles Kooperberg,Loic Le Marchand,Ruth J. F. Loos,Tara C. Matise,Kari E. North,Ulrike Peters,Eimear E. Kenny,Christopher S. Carlson

DOI: https://doi.org/10.1038/s41586-019-1310-4

IF: 64.8

2019-06-01

Nature

Abstract:Genome-wide association studies (GWAS) have laid the foundation for investigations into the biology of complex traits, drug development and clinical guidelines. However, the majority of discovery efforts are based on data from populations of European ancestry<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="/articles/s41586-019-1310-4#ref-CR3">3</a>. In light of the differential genetic architecture that is known to exist between populations, bias in representation can exacerbate existing disease and healthcare disparities. Critical variants may be missed if they have a low frequency or are completely absent in European populations, especially as the field shifts its attention towards rare variants, which are more likely to be population-specific<a href="#ref-CR4">4</a>,<a href="#ref-CR5">5</a>,<a href="#ref-CR6">6</a>,<a href="#ref-CR7">7</a>,<a href="#ref-CR8">8</a>,<a href="#ref-CR9">9</a>,<a href="/articles/s41586-019-1310-4#ref-CR10">10</a>. Additionally, effect sizes and their derived risk prediction scores derived in one population may not accurately extrapolate to other populations<a href="/articles/s41586-019-1310-4#ref-CR11">11</a>,<a href="/articles/s41586-019-1310-4#ref-CR12">12</a>. Here we demonstrate the value of diverse, multi-ethnic participants in large-scale genomic studies. The Population Architecture using Genomics and Epidemiology (PAGE) study conducted a GWAS of 26 clinical and behavioural phenotypes in 49,839 non-European individuals. Using strategies tailored for analysis of multi-ethnic and admixed populations, we describe a framework for analysing diverse populations, identify 27 novel loci and 38 secondary signals at known loci, as well as replicate 1,444 GWAS catalogue associations across these traits. Our data show evidence of effect-size heterogeneity across ancestries for published GWAS associations, substantial benefits for fine-mapping using diverse cohorts and insights into clinical implications. In the United States—where minority populations have a disproportionately higher burden of chronic conditions<a href="/articles/s41586-019-1310-4#ref-CR13">13</a>—the lack of representation of diverse populations in genetic research will result in inequitable access to precision medicine for those with the highest burden of disease. We strongly advocate for continued, large genome-wide efforts in diverse populations to maximize genetic discovery and reduce health disparities.

multidisciplinary sciences
Recommendations for genetic variation data capture in developing countries to ensure a comprehensive worldwide data collection

George P. Patrinos,Jumana Yousuf Al-Aama,Aida Imbrahim Al Aqeel,Fahd Al-Mulla,Joseph Anthony Borg,Andrew Devereux,Alex E. Felice,Finlay A. Macrae,Makia J. Marafie,Michael Bjorn Petersen,Ming Qi,Rajkumar Kumar Ramesar,Joël Zlotogora,Richard G H Cotton

DOI: https://doi.org/10.1002/humu.21397

2011-01-01

Human Mutation

Abstract:Developing countries have significantly contributed to the elucidation of the genetic basis of both common and rare disorders, providing an invaluable resource of cases due to large family sizes, consanguinity, and potential founder effects. Moreover, the recognized depth of genomic variation in indigenous African populations, reflecting the ancient origins of humanity on the African continent, and the effect of selection pressures on the genome, will be valuable in understanding the range of both pathological and nonpathological variations. The involvement of these populations in accurately documenting the extant genetic heterogeneity is more than essential. Developing nations are regarded as key contributors to the Human Variome Project (HVP; http://www.humanvariomeproject.org), a major effort to systematically collect mutations that contribute to or cause human disease and create a cyber infrastructure to tie databases together. However, biomedical research has not been the primary focus in these countries even though such activities are likely to produce economic and health benefits for all. Here, we propose several recommendations and guidelines to facilitate participation of developing countries in genetic variation data documentation, ensuring an accurate and comprehensive worldwide data collection. We also summarize a few well-coordinated genetic data collection initiatives that would serve as paradigms for similar projects. Hum Mutat 32:2-9, 2011. (C) 2010 Wiley-Liss, Inc.
African genetic diversity and adaptation inform a precision medicine agenda

Luisa Pereira,Leon Mutesa,Paulina Tindana,Michèle Ramsay

DOI: https://doi.org/10.1038/s41576-020-00306-8

IF: 59.581

2021-01-11

Nature Reviews Genetics

Abstract:The deep evolutionary history of African populations, since the emergence of modern humans more than 300,000 years ago, has resulted in high genetic diversity and considerable population structure. Selected genetic variants have increased in frequency due to environmental adaptation, but recent exposures to novel pathogens and changes in lifestyle render some of them with properties leading to present health liabilities. The unique discoverability potential from African genomic studies promises invaluable contributions to understanding the genomic and molecular basis of health and disease. Globally, African populations are understudied, and precision medicine approaches are largely based on data from European and Asian-ancestry populations, which limits the transferability of findings to the continent of Africa. Africa needs innovative precision medicine solutions based on African data that use knowledge and implementation strategies aligned to its climatic, cultural, economic and genomic diversity.

genetics & heredity
Darwinian genomics and diversity in the tree of life

Taylorlyn Stephan,Shawn M. Burgess,Hans Cheng,Charles G. Danko,Clare A. Gill,Erich D. Jarvis,Klaus-Peter Koepfli,James E. Koltes,Eric Lyons,Pamela Ronald,Oliver A. Ryder,Lynn M. Schriml,Pamela Soltis,Sue VandeWoude,Huaijun Zhou,Elaine A. Ostrander,Elinor K. Karlsson

DOI: https://doi.org/10.1073/pnas.2115644119

IF: 11.1

2022-01-18

Proceedings of the National Academy of Sciences

Abstract:Genomics encompasses the entire tree of life, both extinct and extant, and the evolutionary processes that shape this diversity. To date, genomic research has focused on humans, a small number of agricultural species, and established laboratory models. Fewer than 18,000 of ∼2,000,000 eukaryotic species (<1%) have a representative genome sequence in GenBank, and only a fraction of these have ancillary information on genome structure, genetic variation, gene expression, epigenetic modifications, and population diversity. This imbalance reflects a perception that human studies are paramount in disease research. Yet understanding how genomes work, and how genetic variation shapes phenotypes, requires a broad view that embraces the vast diversity of life. We have the technology to collect massive and exquisitely detailed datasets about the world, but expertise is siloed into distinct fields. A new approach, integrating comparative genomics with cell and evolutionary biology, ecology, archaeology, anthropology, and conservation biology, is essential for understanding and protecting ourselves and our world. Here, we describe potential for scientific discovery when comparative genomics works in close collaboration with a broad range of fields as well as the technical, scientific, and social constraints that must be addressed.

multidisciplinary sciences
Ambitious survey of human diversity yields millions of undiscovered genetic variants

Max Kozlov

DOI: https://doi.org/10.1038/d41586-024-00502-0

IF: 64.8

2024-02-21

Nature

Abstract:Analysis of the 'All of Us' genomic data set begins to tackle inequities in genetics research. Analysis of the 'All of Us' genomic data set begins to tackle inequities in genetics research.

multidisciplinary sciences
Diverse ancestral representation improves genetic intolerance metrics

Alexander Han,Chloe F. Sands,Dorota Matelska,Jessica C. Butts,Vida Ravanmehr,Fengyuan Hu,Esmeralda Villavicencio Gonzalez,Nicholas Katsanis,Carlos D. Bustamante,Quanli Wang,Slavé Petrovski,Dimitrios Vitsios,Ryan S Dhindsa

DOI: https://doi.org/10.1101/2024.11.04.621955

2024-11-06

Abstract:Rapidly expanding genomic databases have enabled the identification of regions in the human genome intolerant to variation and thus likely relevant to human disease. However, despite their unprecedented scale, these datasets remain constrained by limited ancestral diversity. Here, we systematically evaluate how genetic diversity impacts gene- and sub-genic intolerance metrics by analyzing whole-exome sequencing data from 460,551 UK Biobank participants and 125,748 gnomAD participants across diverse ancestral backgrounds. Through comprehensive analysis of randomly sampled datasets with varying ancestral compositions, we demonstrate that genetic diversity, rather than sample size alone, drives the performance of intolerance metrics in identifying functionally critical genes and genic sub-regions. Notably, scores trained on variation observed in African and Admixed American ancestral groups showed superior resolution in detecting neurodevelopmental disease risk genes and haploinsufficient genes compared to scores trained on variation observed in European ancestry cohorts. Most strikingly, the Missense Tolerance Ratio (MTR) trained on 43,000 multi-ancestry exomes demonstrated greater predictive power than when trained on a nearly 10-fold larger dataset of 440,000 non-Finnish European exomes, indicating that European ancestry-based scores are approaching saturation. These findings establish ancestral diversity as the fundamental determinant for advancing intolerance metrics and underscore the urgent scientific and ethical imperative for enhanced population representation in genomic resources to fully realize the potential of precision medicine and drug discovery.

Genetics
A brief history of human disease genetics

Melina Claussnitzer,Judy H. Cho,Rory Collins,Nancy J. Cox,Emmanouil T. Dermitzakis,Matthew E. Hurles,Sekar Kathiresan,Eimear E. Kenny,Cecilia M. Lindgren,Daniel G. MacArthur,Kathryn N. North,Sharon E. Plon,Heidi L. Rehm,Neil Risch,Charles N. Rotimi,Jay Shendure,Nicole Soranzo,Mark I. McCarthy

DOI: https://doi.org/10.1038/s41586-019-1879-7

IF: 64.8

2020-01-08

Nature

Abstract:A primary goal of human genetics is to identify DNA sequence variants that influence biomedical traits, particularly those related to the onset and progression of human disease. Over the past 25 years, progress in realizing this objective has been transformed by advances in technology, foundational genomic resources and analytical tools, and by access to vast amounts of genotype and phenotype data. Genetic discoveries have substantially improved our understanding of the mechanisms responsible for many rare and common diseases and driven development of novel preventative and therapeutic strategies. Medical innovation will increasingly focus on delivering care tailored to individual patterns of genetic predisposition.

multidisciplinary sciences
Leveraging genomic diversity to promote human and animal health

Michèle Ramsay,Han G Brunner,Appolinaire Djikeng

DOI: https://doi.org/10.1038/s42003-019-0708-8

2019-12-11

Abstract:Genomic diversity is a driving force influencing human and animal health, and susceptibility to disease. During the Keystone Symposium on Leveraging Genomic Diversity to Promote Human and Animal Health held in Kampala on Lake Victoria in Uganda, we brought together diverse communities of geneticists with primary objectives to explore areas of common interest, joint technological and methodological developments and applications, and to leverage opportunities for cross-learning. We explored translational genomics research in farmed animals and humans, debated the differences in research objectives in high- and low-resourced environments, delved into infectious diseases and zoonoses affecting humans and animals and considered diversity and cultural context at many levels. The 109 participants were from 22 countries (13 in Africa) and included 44 global travel awardees from 9 countries, equal numbers of men and women, of whom 31 were students and 13 senior investigators.
A harmonized public resource of deeply sequenced diverse human genomes

Zan Koenig,Mary T. Yohannes,Lethukuthula L. Nkambule,Xuefang Zhao,Julia K. Goodrich,Heesu Ally Kim,Michael W. Wilson,Grace Tiao,Stephanie P. Hao,Nareh Sahakian,Katherine R. Chao,Mark A. Walker,Yunfei Lyu,Heidi L. Rehm,Benjamin M. Neale,Michael E. Talkowski,Mark J. Daly,Harrison Brand,Konrad J. Karczewski,Elizabeth G. Atkinson,Alicia R. Martin,gnomAD Project Consortium

DOI: https://doi.org/10.1101/gr.278378.123

IF: 9.438

2024-06-26

Genome Research

Abstract:Underrepresented populations are often excluded from genomic studies owing in part to a lack of resources supporting their analyses. The 1000 Genomes Project (1kGP) and Human Genome Diversity Project (HGDP), which have recently been sequenced to high coverage, are valuable genomic resources because of the global diversity they capture and their open data sharing policies. Here, we harmonized a high-quality set of 4094 whole genomes from 80 populations in the HGDP and 1kGP with data from the Genome Aggregation Database (gnomAD) and identified over 153 million high-quality SNVs, indels, and SVs. We performed a detailed ancestry analysis of this cohort, characterizing population structure and patterns of admixture across populations, analyzing site frequency spectra, and measuring variant counts at global and subcontinental levels. We also show substantial added value from this data set compared with the prior versions of the component resources, typically combined via liftOver and variant intersection; for example, we catalog millions of new genetic variants, mostly rare, compared with previous releases. In addition to unrestricted individual-level public release, we provide detailed tutorials for conducting many of the most common quality-control steps and analyses with these data in a scalable cloud-computing environment and publicly release this new phased joint callset for use as a haplotype resource in phasing and imputation pipelines. This jointly called reference panel will serve as a key resource to support research of diverse ancestry populations.

biochemistry & molecular biology,biotechnology & applied microbiology,genetics & heredity
Global genomic diversity for All of Us

Linda Koch

DOI: https://doi.org/10.1038/s41576-024-00727-9

IF: 59.581

2024-03-21

Nature Reviews Genetics

Abstract:A publication in Nature reports the data release of around 245,000 clinical-grade whole-genome sequences as part of the NIH's All of Us Research Programme. Several companion papers highlight the value of better capturing global genomic diversity.

genetics & heredity
Public data and open source tools for multi-assay genomic investigation of disease

Lavanya Kannan,Marcel Ramos,Angela Re,Nehme El-Hachem,Zhaleh Safikhani,Deena M.A. Gendoo,Sean Davis,David Gomez-Cabrero,Robert Castelo,Kasper D. Hansen,Vincent J. Carey,Martin Morgan,Aedín C. Culhane,Benjamin Haibe-Kains,Levi Waldron

DOI: https://doi.org/10.1093/bib/bbv080

IF: 9.5

2015-10-12

Briefings in Bioinformatics

Abstract:Molecular interrogation of a biological sample through DNA sequencing, RNA and microRNA profiling, proteomics and other assays, has the potential to provide a systems level approach to predicting treatment response and disease progression, and to developing precision therapies. Large publicly funded projects have generated extensive and freely available multi-assay data resources; however, bioinformatic and statistical methods for the analysis of such experiments are still nascent. We review multi-assay genomic data resources in the areas of clinical oncology, pharmacogenomics and other perturbation experiments, population genomics and regulatory genomics and other areas, and tools for data acquisition. Finally, we review bioinformatic tools that are explicitly geared toward integrative genomic data visualization and analysis. This review provides starting points for accessing publicly available data and tools to support development of needed integrative methods.

biochemical research methods,mathematical & computational biology
Abstract 2948: Unveiling hidden genomic diversity: Exploring epigenetic potential and gene expression in African Pan Genome contig sequences

Rachel Martini,Kyriaki Founta,Sebastian Maurice,Jason White,Onyinye Balogun,Nyasha Chambwe,Melissa Davis

DOI: https://doi.org/10.1158/1538-7445.am2024-2948

IF: 11.2

2024-03-31

Cancer Research

Abstract:An important consideration when studying cancer in diverse populations is the representativeness of the reference genome. Cancer genomics findings are largely based upon alignments to GRCh37 and GRCh38 references, and with the recent release of the telomere-to-telomere (T2T) and the Human Pangenome Reference Consortium references, analyses of sequences distinct from previous references in the cancer context provide exciting opportunities to identify novel targets that may be linked to cancer outcomes. Because GRCh38 and T2T are overwhelmingly Eurocentric, the question remains if these references have applicability outside the ancestral populations that comprise them. Prior to T2T and pangenome, whole genome sequencing of 910 individuals of African descent revealed 296.5 million distinct base pairs, which were assembled into 125,715 African Pan Genome (APG) contigs. These unique sequences represent African ancestry novel genomic sequences whose function was unclear. Here we present provisional efforts to determine the function of APG contigs, and whether they are represented in newer references. To determine the epigenetic potential of the 125,715 APG contigs, we used Emboss Cpgplot to predict CpG islands. We identified 8,353 potential CpG islands, where 6,352 contigs had at least 1 predicted CpG island, and 1 contig had 9. There was weak correlation between contig length, GC content and number of predicted CpG islands suggesting that these sequences represented potentially functional regions. Using unmapped transcriptomic reads from our published African ancestry triple negative breast cancer cohort, we sought to determine the expression potential of these contigs. Unmapped reads mapped to ~9% of the contigs, where ~1100 APG contigs had both predicted CpG islands and alignment of the unmapped transcriptomic reads. This strongly suggests that these APG contigs contain African ancestry-specific regulatory regions and functional gene coding sequences. Preliminary BLASTn queries of contigs with regulatory potential revealed that these sequences may be present in T2T. Mapping to T2T and visualization of expression and CpG islands showed that our predictions matched novel T2T sequences. We anticipated some contigs would map to T2T given one- or two-end placement in GRCh38 and wanted to determine if any of the ~1100 contigs mapped to T2T. Initial analysis of this contig subset shows ~15% fail to map to T2T, indicating that T2T may still fail to capture diversity across ancestry groups. These sequences represent previously unstudied expression and epigenetic potential not captured in the reference genome, and we are working to evaluate all 125,715 sequences. Capturing the diversity across the genome remains extremely important to contextualize these findings and build resources to continue moving precision medicine approaches forward across diverse ancestry groups. Citation Format: Rachel Martini, Kyriaki Founta, Sebastian Maurice, Jason White, Onyinye Balogun, Nyasha Chambwe, Melissa Davis. Unveiling hidden genomic diversity: Exploring epigenetic potential and gene expression in African Pan Genome contig sequences [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2948.

oncology
Population genetic considerations for using biobanks as international resources in the pandemic era and beyond

Hannah Carress,Daniel John Lawson,Eran Elhaik

DOI: https://doi.org/10.1186/s12864-021-07618-x

IF: 4.547

2021-05-17

BMC Genomics

Abstract:The past years have seen the rise of genomic biobanks and mega-scale meta-analysis of genomic data, which promises to reveal the genetic underpinnings of health and disease. However, the over-representation of Europeans in genomic studies not only limits the global understanding of disease risk but also inhibits viable research into the genomic differences between carriers and patients. Whilst the community has agreed that more diverse samples are required, it is not enough to blindly increase diversity; the diversity must be quantified, compared and annotated to lead to insight. Genetic annotations from separate biobanks need to be comparable and computable and to operate without access to raw data due to privacy concerns. Comparability is key both for regular research and to allow international comparison in response to pandemics. Here, we evaluate the appropriateness of the most common genomic tools used to depict population structure in a standardized and comparable manner. The end goal is to reduce the effects of confounding and learn from genuine variation in genetic effects on phenotypes across populations, which will improve the value of biobanks (locally and internationally), increase the accuracy of association analyses and inform developmental efforts.
Understanding Human Diseases with High-Throughput Quantitative Measurement and Analysis of Molecular Signatures

Li Yang,Gang Wei,Kun Tang,Christine Nardini,Jing-Dong J. Han

DOI: https://doi.org/10.1007/s11427-013-4445-9

2013-01-01

Scientia Sinica Vitae

Abstract:Microarray and deep sequencing technologies have provided unprecedented opportunities for mapping genome mutations, RNA transcripts, transcription factor binding, and histone modifications at high resolution at the genome-wide level. This has revolutionized the way in which transcriptomes, regulatory networks and epigenetic regulations have been studied and large amounts of heterogeneous data have been generated. Although efforts are being made to integrate these datasets unbiasedly and efficiently, how best to do this still remains a challenge. Here we review major impacts of high-throughput genome-wide data generation, their relevance to human diseases, and various bioinformatics approaches for data integration. Finally, we provide a case study on inflammatory diseases.
Abstract B012: Prioritization of ancestry-specific variations in disease data helps to alleviate bias in genomic data

Leslie A. Smith,Kiley Graim,James A. Cahill

DOI: https://doi.org/10.1158/1538-7755.disp24-b012

2024-09-23

Cancer Epidemiology Biomarkers & Prevention

Abstract:95% of sequencing data is from individuals of European descent. Underrepresentation of non- European individuals in genomic resources has limited our understanding of the effects of population-specific variants on complex traits and disease. Human populations have undergone selection for variants beneficial to survival in their environment, resulting in individuals with genetic variants unique to their ancestral populations. While these variants can impact disease occurrence and treatment outcome, genetic ancestry is often unaccounted for in disease modeling. Lack of ancestral population representation in data has led to disparate disease outcomes and treatment. While the primary proposed solution to this problem is more diverse sequencing of patients, these efforts will take years of effort and continual work to maintain the diversity balance. Additionally, they will not solve the issue; clinical trials cannot expect to capture human global diversity at every stage. Here we show we can mitigate data bias by utilizing readily available genomic population databases to target genes with ancestrally relevant variations. Our AI model, PhyloFrame, creates equitable gene signatures from transcriptomic input data. PhyloFrame corrects for ancestral bias in data by utilizing genomic population databases and functional interaction networks to identify genes both relevant to disease and associated with a variant unique to a single ancestry. PhyloFrame uses gnomAD data to quantify genome-wide ancestry-specific allele frequencies from a large cohort of healthy individuals, which PhyloFrame uses to create ancestry-agnostic signatures when modeling disease data. Our model demonstrates the utility of including readily available population-level data from healthy individuals in AI methods to overcome existing genomic data bias. PhyloFrame serves also as a demonstration of how equitable AI methods create gene signatures applicable across ancestries without requiring sample-specific ancestry information. Our model demonstrates how AI can be used to help mitigate ancestral bias in genomic data using preexisting data and contribute to equitable representation in medical research. Citation Format: Leslie A. Smith, Kiley Graim, James A. Cahill. Prioritization of ancestry-specific variations in disease data helps to alleviate bias in genomic data [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl) nr B012.

oncology,public, environmental & occupational health
Discovery of genetic risk factors for disease

Grant W. Montgomery

DOI: https://doi.org/10.1080/03036758.2017.1392324

2017-11-02

Journal of the Royal Society of New Zealand

Abstract:Advances in genomics have led to discovery of hundreds of mutations causing rare diseases and thousands of risk loci for complex diseases. As methods developed, I applied these first to map major genes in livestock and, more recently, to map genetic risk factors for common human diseases including melanoma and endometriosis. Genome-wide association studies (GWAS) have identified c. 10,000 genetic risk factors for human traits or diseases. These effects are small and a major challenge is that the results cannot be immediately translated into better understanding of disease biology or new drug targets. Major international efforts are in progress to bridge this gap and speed up target gene discovery with studies on genetic control of gene expression, epigenetic regulation and new high throughput methods to screen for functional consequences of GWAS ‘hits’. Understanding the genetic basis of disease is beginning to identify new drug targets, clarify the roles of environmental and biochemical exposures on disease development, and identify variants determining individual response to drugs. Translation and clinical applications will accelerate as the challenges to target gene identification are overcome. Grant W. Montgomery.

multidisciplinary sciences
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases

Muin J Khoury,Lars Bertram,Paolo Boffetta,Adam S Butterworth,Stephen J Chanock,Siobhan M Dolan,Isabel Fortier,Montserrat Garcia-Closas,Marta Gwinn,Julian P T Higgins,A Cecile J W Janssens,James Ostell,Ryan P Owen,Roberta A Pagon,Timothy R Rebbeck,Nathaniel Rothman,Jonine L Bernstein,Paul R Burton,Harry Campbell,Anand Chockalingam,Helena Furberg,Julian Little,Thomas R O'Brien,Daniela Seminara,Paolo Vineis,Deborah M Winn,Wei Yu,John P A Ioannidis

DOI: https://doi.org/10.1093/aje/kwp119

2009-08-01

Abstract:Genome-wide association studies (GWAS) have led to a rapid increase in available data on common genetic variants and phenotypes and numerous discoveries of new loci associated with susceptibility to common complex diseases. Integrating the evidence from GWAS and candidate gene studies depends on concerted efforts in data production, online publication, database development, and continuously updated data synthesis. Here the authors summarize current experience and challenges on these fronts, which were discussed at a 2008 multidisciplinary workshop sponsored by the Human Genome Epidemiology Network. Comprehensive field synopses that integrate many reported gene-disease associations have been systematically developed for several fields, including Alzheimer's disease, schizophrenia, bladder cancer, coronary heart disease, preterm birth, and DNA repair genes in various cancers. The authors summarize insights from these field synopses and discuss remaining unresolved issues -- especially in the light of evidence from GWAS, for which they summarize empirical P-value and effect-size data on 223 discovered associations for binary outcomes (142 with P < 10(-7)). They also present a vision of collaboration that builds reliable cumulative evidence for genetic associations with common complex diseases and a transparent, distributed, authoritative knowledge base on genetic variation and human health. As a next step in the evolution of Human Genome Epidemiology reviews, the authors invite investigators to submit field synopses for possible publication in the American Journal of Epidemiology.
Population Diversity at the Single-Cell Level

M. Grace Gordon,Pooja Kathail,Bryson Choy,Min Cheol Kim,Thomas Mazumder,Melissa Gearing,Chun Jimmie Ye

DOI: https://doi.org/10.1146/annurev-genom-021623-083207

2024-02-21

Annual Review of Genomics and Human Genetics

Abstract:Population-scale single-cell genomics is a transformative approach for unraveling the intricate links between genetic and cellular variation. This approach is facilitated by cutting-edge experimental methodologies, including the development of high-throughput single-cell multiomics and advances in multiplexed environmental and genetic perturbations. Examining the effects of natural or synthetic genetic variants across cellular contexts provides insights into the mutual influence of genetics and the environment in shaping cellular heterogeneity. The development of computational methodologies further enables detailed quantitative analysis of molecular variation, offering an opportunity to examine the respective roles of stochastic, intercellular, and interindividual variation. Future opportunities lie in leveraging long-read sequencing, refining disease-relevant cellular models, and embracing predictive and generative machine learning models. These advancements hold the potential for a deeper understanding of the genetic architecture of human molecular traits, which in turn has important implications for understanding the genetic causes of human disease. Expected final online publication date for the Annual Review of Genomics and Human Genetics, Volume 25 is August 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

genetics & heredity
Applications of single-cell genomics and computational strategies to study common disease and population-level variation

Benjamin J. Auerbach,Jian Hu,Muredach P. Reilly,Mingyao Li

DOI: https://doi.org/10.1101/gr.275430.121

IF: 9.438

2021-10-01

Genome Research

Abstract:The advent and rapid development of single-cell technologies have made it possible to study cellular heterogeneity at an unprecedented resolution and scale. Cellular heterogeneity underlies phenotypic differences among individuals, and studying cellular heterogeneity is an important step toward our understanding of the disease molecular mechanism. Single-cell technologies offer opportunities to characterize cellular heterogeneity from different angles, but how to link cellular heterogeneity with disease phenotypes requires careful computational analysis. In this article, we will review the current applications of single-cell methods in human disease studies and describe what we have learned so far from existing studies about human genetic variation. As single-cell technologies are becoming widely applicable in human disease studies, population-level studies have become a reality. We will describe how we should go about pursuing and designing these studies, particularly how to select study subjects, how to determine the number of cells to sequence per subject, and the needed sequencing depth per cell. We also discuss computational strategies for the analysis of single-cell data and describe how single-cell data can be integrated with bulk tissue data and data generated from genome-wide association studies. Finally, we point out open problems and future research directions.

genetics & heredity,biochemistry & molecular biology,biotechnology & applied microbiology

Genomic diversity improves disease discovery for all

Genetic analyses of diverse populations improves discovery for complex traits

Recommendations for genetic variation data capture in developing countries to ensure a comprehensive worldwide data collection

African genetic diversity and adaptation inform a precision medicine agenda

Darwinian genomics and diversity in the tree of life

Ambitious survey of human diversity yields millions of undiscovered genetic variants

Diverse ancestral representation improves genetic intolerance metrics

A brief history of human disease genetics

Leveraging genomic diversity to promote human and animal health

A harmonized public resource of deeply sequenced diverse human genomes

Global genomic diversity for All of Us

Public data and open source tools for multi-assay genomic investigation of disease

Abstract 2948: Unveiling hidden genomic diversity: Exploring epigenetic potential and gene expression in African Pan Genome contig sequences

Population genetic considerations for using biobanks as international resources in the pandemic era and beyond

Understanding Human Diseases with High-Throughput Quantitative Measurement and Analysis of Molecular Signatures

Abstract B012: Prioritization of ancestry-specific variations in disease data helps to alleviate bias in genomic data

Discovery of genetic risk factors for disease

Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases

Population Diversity at the Single-Cell Level

Applications of single-cell genomics and computational strategies to study common disease and population-level variation